The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
July 27th 2019, 4:59am
International Lung Cancer Congress
The frontline standard of care for patients with EGFR-mutant non–small cell lung cancer remains an EGFR TKI, most commonly osimertinib in the United States.
July 27th 2019, 4:38am
International Lung Cancer Congress
Checkpoint inhibitors in the neoadjuvant setting, as consolidation post-chemoradiation, or in combination with concurrent chemoradiation, are all strategies actively being pursued in the locally advanced non–small cell lung cancer setting.
July 26th 2019, 11:54pm
International Lung Cancer Congress
The future generation of agents in lung cancer should be evaluated in improved predictive biomarker-driven trials to identify patients who are most likely to benefit or have detriment for both TKIs and checkpoint inhibitors.
July 26th 2019, 5:46am
International Lung Cancer Congress
Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses combinations with immunotherapy in lung cancer.
July 26th 2019, 5:37am
International Lung Cancer Congress
Karen L. Reckamp, MD, MS, discusses pivotal findings with the highly selective MET inhibitors, tepotinib and capmatinib in patients with MET exon 14-altered advanced non–small cell lung cancer.
July 26th 2019, 4:20am
International Lung Cancer Congress
There is a growing need to share information across research settings and the community, with the rapid introduction of new biomarkers, cancer detection strategies, immunotherapies, and targeted therapies. This synchronization of system biology tool datasets could help create a new digital ecosystem focused on precision medicine.
July 26th 2019, 4:13am
International Lung Cancer Congress
Paul A. Bunn Jr, MD, highlights the benefits of preoperative window-of-opportunity studies, specifically with immunotherapy in lung cancer.
July 26th 2019, 2:09am
International Lung Cancer Congress
Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic.
June 22nd 2019, 2:02am
International Conference on Malignant Lymphoma
Patients with high-risk relapsed/refractory chronic lymphocytic leukemia who failed or were intolerant of ibrutinib derived more benefit from CD19‐targeted CAR T-cell therapy when the BTK inhibitor was concurrently administered than when it was not.
June 21st 2019, 11:53pm
International Conference on Malignant Lymphoma
Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
June 21st 2019, 11:21pm
International Conference on Malignant Lymphoma
Nearly three-fourths of patients with relapsed/refractory primary mediastinal large B-cell lymphoma responded to a combination of nivolumab (Opdivo) plus brentuximab vedotin (Adcetris).
June 21st 2019, 10:41pm
International Conference on Malignant Lymphoma
The CAR T-cell therapy lisocabtagene maraleucel demonstrated high rates of response, including minimum residual disease in blood and marrow in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
June 21st 2019, 8:50pm
International Conference on Malignant Lymphoma
S. Vincent Rajkumar, MD, discusses the rapidly changing landscape for the treatment of multiple myeloma, the future of immunomodulatory drugs, and whether quadruplet regimens will become more frequent.
June 21st 2019, 6:05pm
International Conference on Malignant Lymphoma
Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.
June 21st 2019, 12:31am
International Conference on Malignant Lymphoma
Acalabrutinib elicited high rates of response as well as prolonged survival and was well tolerated in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib.
June 20th 2019, 11:46pm
International Conference on Malignant Lymphoma
In a careful evaluation of chemotherapy‐free regimens, the combination of obinutuzumab plus venetoclax compared to obinutuzumab plus chlorambucil, objective and complete response rates, as well as progression-free survival were superior with the venetoclax combination in the overall study population and across all genetic subgroups evaluated in patients with chronic lymphocytic lymphoma.
June 20th 2019, 11:20pm
International Conference on Malignant Lymphoma
The phase III ASCEND trial is only one of the pivotal trials that have presented data to suggest that acalabrutinib (Calquence) could see an FDA approval for the frontline treatment of patients with chronic lymphocytic leukemia.
June 20th 2019, 7:56pm
International Conference on Malignant Lymphoma
Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.
June 20th 2019, 7:38pm
International Conference on Malignant Lymphoma
S. Vincent Rajkumar, a professor of Medicine at the Mayo Clinic, Rochester, Minnesota, discusses the prevalence of quadruplet regimens in treating patients with multiple myeloma.
June 20th 2019, 1:31am
International Conference on Malignant Lymphoma
Jennifer R. Brown, MD, PhD, highlights the new and upcoming research regarding acalabrutinib in the field of chronic lymphocytic leukemia.